Skip to main content

Atopic Dermatitis (Eczema) clinical trials at UC Davis

6 research studies open to eligible people

Showing trials for
  • A Study of Experimental Baricitinib (LY3009104) for Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18 years and up

    This open-label study will evaluate the long-term efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis (AD), who have completed participation in study BREEZE-AD5/Study JAIW (NCT03435081). This 204-week outpatient study, includes a treatment period of approximately 200-weeks and up to 17 planned study visits.

    Sacramento, California and other locations

  • A Study of Experimental Upadacitinib in Adolescents and Adults With Moderate to Severe Atopic Dermatitis (Eczema)

    open to eligible people ages 12-75

    The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe Atopic Dermatitis (AD) who are candidates for systemic therapy.

    Sacramento, California and other locations

  • Atopic Dermatitis (Eczema) Study

    open to eligible people ages 18 years and up

    The purpose of this study is to evaluate the efficacy and safety of baricitinib in adult participants with moderate to severe atopic dermatitis.

    Sacramento, California and other locations

  • Extension Study to Test Effectiveness and Safety of Experimental PF-04965842 for Adolescents With Atopic Dermatitis

    open to eligible people ages 12 years and up

    B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to severe atopic dermatitis and have completed a qualifying Phase 3 study. The efficacy and safety of two dosage strengths of Abrocitinib, 100 mg and 200 mg taken orally once daily, will be evaluated over variable lengths of study participation. The study consists of a 92 week initial treatment period followed by a variable length secondary treatment period during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country

    Sacramento, California and other locations

  • Safety and Effectiveness of Experimental Upadacitinib vs. Dupilumab in Adults With Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18-75

    This is a phase 3, randomized, multi-center study that will evaluate upadacitinib versus dupilumab in adults (18-75 years of age) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy. The study is comprised of a 35-day screening period, a 24-week blinded treatment period, and a 12-week follow-up period.

    Sacramento, California and other locations

  • Study of Experimental JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

    open to eligible people ages 12-17

    This is a randomized, double blind, placebo controlled, parallel group, Phase 3 study to evaluate the efficacy and safety of PF 04965842 in adolescent participants 12 to <18 years of age with moderate to severe AD.

    Sacramento, California and other locations

Last updated: